Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...
RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.
Glaucoma symptoms vary depending on the type of disease. The most common form in the United States, open-angle glaucoma, develops gradually, causing blind spots in peripheral vision that may go ...
In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.
Don't miss out on the headlines from News. Followed categories will be added to My News. The Seagulls downed Anglesea in the A1 grand final last March in its first season post-promotion, as the ...
It will be a grand final rematch in the BPCA’s top tier as Wallington and Collendina approach A2 semi-finals in magnificent batting form after historic deeds. The Seagulls downed Anglesea in the ...
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...